BSI-128 (AK2024) enhances trastuzumab function and potentiates trastuzumab-deruxtecan activity across HER2-positive preclinical models

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

Perjeta (pertuzumab) - Roche

BSI-128 - Biosion, Anhui Anke Biotech

https://www.abstractsonline.com/pp8/#!/21436/presentation/4388

Hui-Han Hu1; Yinghui Dou2; Hongyan Li1; Liansheng Cheng2; Jinyu Liu1; Li Wei2; Wenwen Dai1; Daoqin Liu2; Hui Wang1; Ting Xu2; Xiaoyao Hao1; Yue Gao1; Jinge Zhao1; Yi Lu1; Mingjiu Chen1; Kedan Lin3

Mar 18, 2026